Skip to main content

Table 3 Combination antibody therapies under investigation

From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Start year for vaccine trials including mAB combinations

 

Start year

1997

1998

1999

2000

2001

2002

2004

2005

2006

2008

2009

2010

2011

2012

2013

2014

2015

Total

Anti-idiotypic antibody

3H1

    

1

            

1

 Lung

   

1

            

1

BEC2 mab

1

1

              

2

 Lung

1

1

              

2

Racotumomab

         

1

     

1

 NSCLC

          

1

     

1

Targeted

Bevacizumab

         

1

2

 

1

1

  

5

 Brain

             

1

  

1

 Colorectal Cancer

         

1

     

1

 Lung

          

1

     

1

 Ovarian Cancer

           

1

   

1

 Renal Cell Cancer (RCC)

       

1

      

1

Cetuximab

      

1

    

1

    

2

 Colorectal Cancer

          

1

    

1

 Pancreatic Cancer

     

1

         

1

Erlotinib

           

1

    

1

 NSCLC

           

1

    

1

Trastuzumab (Herceptin)

   

1

1

1

1

1

  

1

1

  

7

 Breast Cancer

    

1

1

1

1

1

  

1

1

  

7

Rituximab

  

1

  

2

 

1

 

2

      

6

 Leukemia

       

1

        

1

 Lymphoma

 

1

  

2

   

2

      

5

Immune-suppressive

Daclizumab

           

1

    

1

 Melanoma

           

1

    

1

muromonab-CD3

2

     

1

          

3

 Brain

1

                

1

 Melanoma

1

     

1

          

2

Checkpoint inhibitor

Ipilimumab

    

1

3

 

1

     

1

1

 

7

 Melanoma

    

1

3

 

1

      

1

 

6

 Pancreatic Cancer

            

1

  

1

nivolumab

               

1

1

 Pancreatic Cancer

              

1

1

Pidilizumab (CT-011)

        

2

1

1

   

4

 Leukemia

          

1

     

1

 Myeloma

          

1

     

1

 Neoplasm

            

1

   

1

 Renal Cell Cancer (RCC)

         

1

    

1

 

Total

2

1

1

1

1

1

7

2

3

1

4

5

4

3

3

1

1

41